A method for shearing a plurality of layered amorphous alloy foils 28 includes blanking the plurality of amorphous alloy foils 28 with a shear tool having a punch 12 and a die 14 through one descending of the punch 12. The punch 12 has a first edge E1 formed on a tip surface 12a of the punch 12 and a second edge E2 formed on a side peripheral surface 12b of the punch 12. A horizontal distance l between the first edge E1 and the side peripheral surface 12b and a vertical distance h between the second edge E2 and the tip surface 12a are each set in a range of 0.010 mm to 0.050 mm. A vertical distance h is set to 52% or less of the thickness of each amorphous alloy foil 28.
A specimen analyzer including: a measurement part configured to apply light to a measurement sample and a fluorescent dye that stains white blood cells contained in the blood specimen, detect fluorescence from the white blood cells contained in the measurement sample to which the light has been applied, and measure fluorescence signals on the basis of the detected fluorescence; an information processing part configured to generate, on the basis of the fluorescence signals, information about a distribution width of fluorescence intensities regarding a population of neutrophils contained in the measurement sample, and determine information about a degree of severity of an organ dysfunction due to an infection on the basis of the information about the distribution width of the fluorescence intensities regarding the population of neutrophils; and an output part configured to output the information about the degree of severity of the organ dysfunction due to the infection.
The present invention provides a device, a program, a method, and a system for evaluating and improving the episode memory ability of a user. A device according to the present invention has: a display unit that sequentially displays a first information group comprising a plurality of images or voices and a second information group including part of the first information group and comprising a plurality of images or voices, the display being performed for each image or voice; an input unit to which the user inputs, for each image or voice in the second information group displayed on the display unit, a judgement of the user as to whether the first information group and the second information group are the same or different; an evaluation unit that evaluates a memory ability of the user on the basis of a correct answer rate of the judgement input to the input unit; and an output unit that outputs a result of the evaluation by the evaluation unit. The second information group is displayed after a prescribed time elapses after the first information group is displayed.
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
[Problem] To achieve a well balance between tool service life and quality maintenance, by imparting a functional shape to a cutting edge of a punch, when performing a shearing process on an amorphous alloy foil. [Solution] This shearing method involves, by using a shearing tool equipped with a punch 12 and a die 14, punching through multiple layers of amorphous alloy foils 28 with a single downward movement of the punch 12. The punch 12 is equipped with: a first edge E1 which is formed on a punch apical surface 12a; and a second edge E2 which is formed on a punch-side peripheral surface 12b. The horizontal distance l from the first edge E1 to the punch-side peripheral surface 12b and the vertical distance h from the second edge E2 to the punch apical surface 12a are each configured to fall within a range of 0.010-0.050 mm. In addition, the vertical distance h is set to be 52% or less of the sheet thickness of each of the amorphous alloy foils 28.
An examination system that recognizes a glycosylated antigen in Dane particles of hepatitis B virus (HBV) and a neutralizing antibody that recognizes the glycosylated antigen and that exhibits an infection-inhibiting activity. It was elucidated that Dane particles are associated with specific glycan structures, and this enabled the construction of a new detection system for infectious, i.e., nucleic acid-containing, hepatitis B virus particles and the provision of a neutralizing antibody that recognizes a glycosylated antigen and that exhibits an infection-inhibiting activity.
Provided are, inter alia, novel compounds. Also provided are a nucleic acid detection substance and a base pair formed by this polymer, and a nucleic acid drug containing the polymer or base pair. The compounds are represented by formula (A). [In formula (A), X is an aromatic ring group, R1is -OR1a(In the formula, R1arepresents a hydrogen atom or a substituent.) or a phosphoramidite group, R2is a hydrogen atom or a substituent, R3is a halogen atom or -OR3a(In the formula, R3a represents a hydrogen atom or a substituent.).]
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
C07F 9/6558 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
This antenna device comprises: a circular phased array antenna (1) comprising an N number (N being a natural number of at least 3) of first antenna elements arranged at even intervals on a circle and one second antenna element arranged approximately at the center of the circle; and a circular bottom plate (2) having a radius that can be varied by switching control. The first antenna elements and the second antenna element comprise a mono-pole antenna mounted to the bottom plate (2).
H01Q 21/20 - Arrays of individually energised antenna units similarly polarised and spaced apart the units being spaced along, or adjacent to, a curvilinear path
G01S 3/46 - Systems for determining direction or deviation from predetermined direction using antennas spaced apart and measuring phase or time difference between signals therefrom, i.e. path-difference systems
[Problem] To provide a therapeutic agent for acute herpes zoster pain. [Solution] A therapeutic agent for acute herpes zoster pain, which comprises as an active ingredient a hydantoin compound selected from the group consisting of phenytoin, fosphenytoin, mephenytoin, nirvanol, amino(diphenylhydantoin) valeric acid and ethotoin, and a medicinal composition.
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japan)
UNIVERSITY OF TOYAMA (Japan)
Inventor
Narimatsu Hisashi
Angata Kiyohiko
Kaji Hiroyuki
Kuno Atsushi
Sato Takashi
Chiba Yasunori
Togayachi Akira
Shimizu Hiroki
Sogabe Maki
Wagatsuma Takanori
Mizokami Masashi
Korenaga Masaaki
Tajiri Kazuto
Ozawa Tatsuhiko
Abstract
[Problem] To provide an examination system whereby an antigen having a sugar chain added thereto can be recognized in Dane particle of hepatitis B virus (HBV), and a neutralizing antibody that recognizes an antigen having a sugar chain added thereto and exhibits an inhibitory effect on infection. [Solution] By clarifying that Dane particle relates to a specific sugar chain structure, it becomes possible to construct a novel detection system for hepatitis B virus particles which show infectivity, i.e., contain a nucleic acid. Further, it becomes possible thereby to provide a neutralizing antibody that recognizes an antigen having a sugar chain added thereto and exhibits an inhibitory effect on infection.
Disclosed are a cell culture substrate that can be modified from its cell-inadhesibleness to make it cell-adhesible, by a convenient and low-cost treatment, and particularly, a substrate that allows position-specific culture of one or more kinds of cells. The substrate has on its surface a layer made of a photomodifiable polymer that comprises a monomer, as component (A), represented by Formula (1):
wherein R1 denotes hydrogen or a methyl group, and R2 denotes an alkyl group having 1-22 carbon atoms, respectively, and n denotes an integer of 1-30, and a component (B) having a trialkoxysilyl group, which forms a layer.
The purpose of the present invention is to provide a stable and highly immunoactive substance that is a natural extract, exerts no undesirable effects on health, can be safely and easily taken and is highly resistant to heat, pressure, acids, bases and enzymes. For this purpose, provided is an immunoactive substance comprising a plant nucleic acid and/or a fragment thereof.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
Provided is an agent or composition useful for the proliferation of myocytes, etc. The agent or composition comprises component (A) which is at least one member selected from acteoside, echinacoside and salts thereof and component (B) which is at least one member selected from periostin and PKM2.
Provided is an affected part heating system with which treatment by means of non-invasive hyperthermia and oncothermia can be performed by applying a high-frequency current to a human body, and with which it is possible to prevent destruction of cells other than malignant tumors by means of a temperature measuring device. This affected part heating system for heat treating an affected part inside a body is provided with: an electric field generating device which includes a high-frequency power source and a pair of electrodes disposed in such a way as to sandwich the affected part, and which generates an electric field in a region including a malignant tumor C by means of the application of a voltage to the pair of electrodes by the high-frequency power source; a temperature measuring device 16 including a transducer 22 which generates ultrasonic waves directed toward the affected part and receives an ultrasonic wave echo from inside the body, and a temperature calculating circuit 18 which calculates temperature information relating to the inside of a living body on the basis of the echo received by the transducer 22; and a control device which, on the basis of the temperature information measured by the temperature measuring device, controls the voltage applied by the high-frequency power source of the electric field generating device in such a way that the affected part reaches a prescribed temperature.
Disclosed is a substrate for cell culturing use which can be converted from a non-cell-adhesive form to a cell-adhesive form by a simple and inexpensive treatment, particularly a substrate on which one or more types of cells can be cultured in a site-specific manner. The substrate has, on the surface thereof, a photomodifiable polymer which contains a constituent (A) that is a monomer represented by formula (1) [wherein R1 represents a hydrogen atom or a methyl group; R2 represents an alkyl group having 1 to 22 carbon atoms; and n represents an integer of 1 to 30] and a constituent (B) having a trialkoxysilyl group and a layer formed from the photomodifiable polymer.
A combination needleless injector device for delivering a therapeutic effective amount of a fluid agent subcutaneously and a cover sheet for facilitating delivery of residual fluid not delivered by the needleless injector. The needleless injector has a discharge end and a drive end. The discharge end has a relatively small nozzle for fluid to discharge therethrough for delivery subcutaneously to a patient without a needle and the drive end has a piston held by a trigger and wherein a spring is pushed against the piston to drive the piston to then drive a plunger through the ampule to discharge the fluid medicament. The cover sheet has a liquid impermeable layer and an adhesive layer for surrounding an injection site.
Provided is a test method comprising a step for measuring the number of SSEA-3-positive pluripotent stem cells present in a blood sample collected from a subject, the test method providing a prognosis for cerebral infarction in the subject, and the diagnosis or prediction of asymptomatic cerebral infarction or the risk of cerebral infarction after a transient ischemic attack in the subject using the number of pluripotent stem cells as an index.
Provided is a test method comprising a step for measuring the number of SSEA-3-positive pluripotent stem cells present in a blood sample collected from a subject, the test method providing a prognosis for cerebral infarction in the subject, and the diagnosis or prediction of asymptomatic cerebral infarction or the risk of cerebral infarction after a transient ischemic attack in the subject using the number of pluripotent stem cells as an index.
A therapeutic agent for pulmonary hypertension, said therapeutic agent comprising an interleukin-5 receptor (IL-5R) inhibiting compound, and a therapeutic method therefor. More specifically, a therapeutic agent for pulmonary hypertension, said therapeutic agent comprising an antibody capable of specifically binding to the extracellular region of IL-5R or a fragment of the antibody, and a therapeutic method therefor.
A therapeutic agent for pulmonary hypertension, said therapeutic agent comprising an interleukin-5 receptor (IL-5R) inhibiting compound, and a therapeutic method therefor. More specifically, a therapeutic agent for pulmonary hypertension, said therapeutic agent comprising an antibody capable of specifically binding to the extracellular region of IL-5R or a fragment of the antibody, and a therapeutic method therefor.
There is provided a new material that can form a finer pattern and can be applied to adsorption/adhesion control of various cell species, proteins, viruses, and the like without the limitation of the light source. A light-degradable material comprising: a moiety that is capable of bonding to a surface of a substrate through a siloxane bond; and a structural unit of Formula (2-a) and/or Formula (2-b):
1 is an integer of 1 to 200, and n is an integer of 1 to 10).
C08F 230/08 - Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal containing a metal containing silicon
C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
21.
LIGHT-DEGRADABLE MATERIAL, SUBSTRATE AND METHOD FOR PATTERNING SAME
[Problem] To provide a novel material which allows finer patterning and is applicable to the control of adsorption/adhesion of various cell species, proteins, viruses, etc. without restricting the light source. [Solution] A light-degradable material comprising a moiety that is capable of bonding to the surface of a substrate via a siloxane bond, and structural unit(s) represented by formula (2-a) and/or formula (2-b). In formulae (2-a) and (2-b); R2 to R4 represent each a saturated straight-chain alkyl group; X represents a hydrogen atom or an alkyl group; Z represents a carbanion or a sulfo anion; Q represents an ester bond group, a phosphate diester bond group, an amide bond group, an alkylene group, a phenylene group or a combination of these divalent groups; m1 represents an integer of 1-200; and n represents an integer of 1-10.
An amniotic mesenchymal stem cell mass having a high proliferation ability and a high differentiation ability can be produced by a method comprising the steps of: (A) collecting a cell mass of a mesenchymal cell from the amnion of a mammal; (B) subjecting the cell mass of the mesenchymal cell to flow cytometry to thereby sort cells, wherein a specific gate is provided in a scattergram produced in the flow cytometry; (C) and subjecting the sorted cells to subculture. Alternatively, the amniotic mesenchymal stem cell mass having a high proliferation ability and a high differentiation ability can also be produced by a method comprising the steps of: (D) collecting a cell mass of a mesenchymal cell from the amnion of a mammal; (E) subjecting the collected cell mass to initial culture for 2 to 3 days; (F) repeating the subculture of the resultant cell mass three to four times at a low cell concentration; and (G) maintaining the culture of the cells in the same culture dish until the cells become confluent when a fusiform colony of the cells is formed in the subculture.
Disclosed is a probe for measuring the dynamic state of cyclic-AMP response element binding protein (CREB) or actin, which is a substance closely associated with brain functions (e.g., memory formation) in living animals, in real time. Specifically disclosed is a probe which contains luciferase in a form split into an N-terminal-side part and a C-terminal-side part and comprises at least one probe selected from the following probes (1) to (3): (1) a probe containing, in the molecule, a KID domain of CREB, a KIX domain of CREB-binding protein (CBP), the N-terminal-side part of luciferase (LucN) and the C-terminal-side part of luciferase (LucC); (2) (a) a probe composed of two molecules, i.e., a molecule containing the LucN and the KID domain and a molecule containing the LucC and the KIX domain or (b) a probe composed of two molecules, i.e., a molecule containing the LucN and the KIX domain and a molecule containing the LucC and the KID domain; and (3) a probe composed of two molecules, i.e., a molecule containing actin and the LucN and a molecule containing actin and the LucN.
C12Q 1/66 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving luciferase
A01K 67/027 - New or modified breeds of vertebrates
It is intended to provide a biomarker for an allergic disease caused by an allergic reaction that is caused not exclusively by histamine release such as itching, and utilization of the same. Use of Granzyme A as a biomarker makes it possible to provide an indication for an intractable itching skin disease, for which the existing antiallergic drugs are little efficacious, and easily and adequately make a diagnosis of the disease. Also, it makes possible to, for example, make a diagnosis of an allergic disease with an IV type allergy-like reaction not depending on the antigen-antibody reaction system. Screening with the use of Granzyme A enables the development of a novel remedy for an allergic disease. Moreover, a drug capable of specifically controlling the action of a granzyme enables treatment for an allergic disease with little side effect.
patents
